Background {#Sec1}
==========

Alternating hemiplegia of childhood (AHC) is a rare, early-onset neurodevelopmental disorder. Typically, AHC patients have a baseline neurological disorder with intellectual disability and permanent motor manifestations, along with various paroxysmal episodes \[[@CR1]--[@CR6]\]. *ATP1A3* is the main culprit gene, accounting for about 80--90% of cases of AHC \[[@CR1], [@CR5], [@CR6]\].

The *ATP1A3* gene is largely expressed within the brain \[[@CR7], [@CR8]\]. It encodes the α3 catalytic subunit of a transmembrane sodium-potassium pump that plays a critical role in generating and maintaining Na^+^ and K^+^ gradients across the membrane of neurons \[[@CR9], [@CR10]\]. Disease-causing mutations result in lower Na^+^/K^+^ ATP~ase~ activity, thereby altering neurotransmitter release, neuronal excitability, and intracellular signaling \[[@CR9]--[@CR11]\].

Paroxysmal episodes are characterized by a variable combination of motor deficits, movement disorders, oculomotor abnormalities, pain, autonomic disorders, and seizures \[[@CR2]--[@CR4]\]. Their frequency, severity and duration are highly variable, both in a given patient and from one patient to another. They are often triggered by intense emotions, sensory stimuli such as temperature and light changes, fasting, and physical problems such as infections and trauma \[[@CR2]--[@CR4], [@CR12]\]. Paroxysmal manifestations markedly undermine these patients' quality of life, and their treatment is highly problematic \[[@CR13]\]. The mechanism linking Na^+^/K^+^ ATP~ase~ to paroxysmal events in AHC is largely unknown. Both clinical and radiological data have raised the possibility that a transient brain energy deficit might play a critical role for the paroxysmal manifestations of AHC. Clinical observation found similar triggering factors in AHC and in obvious disorders of brain energy metabolism such as GLUT1 deficiency syndrome \[[@CR12], [@CR14], [@CR15]\]. Imaging studies described cerebral glucose hypometabolism on interictal period in human \[[@CR16]\] and in a AHC mouse model (Myshkin mice) \[[@CR17]\]. Furthermore, ketogenic diet, which efficiently compensates for defective cerebral glucose metabolism, has shown some efficacy on AHC paroxysmal episodes \[[@CR14], [@CR15], [@CR18]\].

Triheptanoin (UX007; Ultragenyx Pharmaceuticals Inc.; Novato; USA) is a medium odd-chain triglyceride containing three 7-carbon fatty acids. Its metabolism yields appropriate substrates for both fatty acid metabolism and anaplerosis. Triheptanoin is well tolerated and has been shown to improve clinical manifestations and/or brain metabolism in various disorders associated with patent brain energy deficits, such as glucose transporter deficiency \[[@CR19]\], pyruvate carboxylase deficiency \[[@CR20]\], and Huntington's disease \[[@CR21]\].

The aim of this randomized, double-blind, placebo-controlled crossover study was to assess the safety and efficacy of triheptanoin on paroxysmal episodes in patients with alternating hemiplegia of childhood due to *ATP1A3* mutations.

Methods {#Sec2}
=======

Study design and intervention {#Sec3}
-----------------------------

This was a randomized, double-blind, placebo-controlled crossover study. All study visits took place at the Clinical Investigation Center for Neurosciences at the Brain and Spine Institute of Pitié-Salpêtrière Hospital between March 2015 and May 2016. The crossover study comprised two treatment periods, one with triheptanoin and the other with placebo (safflower oil with an indistinguishable taste and identical packaging), separated by a 4-week washout period (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow chart of trial participants

Each treatment period consisted of a 12 (± 2)-week fixed-dose phase, except that only half the daily dose was given on the first day. A trained dietician determined the daily calorie intake for each patient and adjusted his or her daily menu to ensure both proper treatment administration and an isocaloric diet. The patients were asked to ingest a treatment dose (triheptanoin or placebo) representing around 30% of their usual daily calorie intake. The target dose corresponding to 30% of daily calorie intake was defined by metabolism analysis in rodent study \[[@CR22], [@CR23]\] and previous clinical trials in human \[[@CR19], [@CR24]\]. Treatment was administered during meals, three to four times a day. Treatment was discontinued abruptly for the 4-week washout period, during which the patients resumed their habitual diet. We chose this long washout period to allow rest for the patients between visits 2 and 3. Dietary and therapeutic adherence was assessed by the dietician at visits 2 and 4.

Outcome measures {#Sec4}
----------------

Demographic data were collected at the beginning of the study, along with information on the *ATP1A3* mutation. Clinical and biological assessments were done at each visit. Neurological paroxysmal events related to AHC were assessed during each study phase, based on a comprehensive daily diary kept by the patient and/or primary caregiver. All paroxysmal events were recorded, whether motor (palsy, stiffness, oculomotor or limb movement disorders, dysarthria) seizure or non-motor (headache, fatigue, mood swings), along with their severity (scored 0--3) and their approximate duration in minutes, as previously described \[[@CR19]\]. If a patient had a combination of two motor manifestations within one event, it was counted as one event. A remission period of 15 min during full wakefulness was arbitrarily used to define two different events. A non-motor manifestation was therefore considered as part of a single event if it started within 15mn after the end of the motor event or if it ended within 15 mn before the motor event. At each visit, the evaluating physician reviewed all paroxysmal events. Clinical changes were assessed with the Clinical Global Impression-Improvement Scale (CGI-I, range 0--7), completed both by the physician and by the patient.

Safety was assessed at each visit by means of an adverse events (AE) questionnaire, as well as bodyweight measurement and laboratory tests (serum electrolytes, blood cell counts, hepatic and renal function tests, plasma C5-keto acids \[[@CR19]\]). Hypnosis was offered to support smooth running of blood sampling procedures. Blood was collected in the morning, after an overnight fast (visits 1 and 3), or 90 min after the last intake of the study medication (visits 2 and 4).

The primary endpoint was the total number of paroxysmal events during the triheptanoin and placebo periods. Secondary outcomes were the number of motor-epileptic paroxysmal events, a composite score taking into account both the number of episodes and their severity and duration (cf. equation), interictal neurological manifestations, and the CGI-I.$$\documentclass[12pt]{minimal}
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                \begin{document}$$ Composite score=\frac{\sum_{i=0}^n{Severity}^{\ast } Duration of the most severe symptom}{Number of weeks} $$\end{document}$$

Biochemical analyses {#Sec5}
--------------------

Here, "C5 keto acids" refers to the two species of 5-carbon-unit monocarboxylic acids carrying either 3-keto or 3-hydroxy radicals. Their plasma levels were measured by organic extraction, trimethylsilylation (BSTFA +1% TMCS, Sigma) and gas chromatography-mass spectrometry in SIM mode (Scion TQ mass analyzer, Brüker). Quantification was calibrated on known amounts of unlabeled analytes relative to stable-isotope-labeled internal standards (3,4,5-1^3^C~3~ 3-ketopentanoate from Eurisotop, Saint Aubin, France and 2,2,3,3,4,4,5,5,6,6-d~10~ 6-hydroxyhexanoic acid from Sigma-Aldrich). The concentrations of plasma C3-carnitine, produced only by triheptanoin due to its odd number of carbons, were also measured as described \[[@CR20]\].

Study population {#Sec6}
----------------

We enrolled AHC patients older than 15 years who had a proven *ATP1A3* mutation, had at least six paroxysmal events during the 3 months prior to enrollment, and were on a normal diet.

Patients were excluded if they had past or present severe psychiatric disorders; comorbid medical conditions that would render them unsuitable for the study; cognitive impairment preventing full understanding of the study; and, for women of child-bearing potential, pregnancy, breastfeeding and nonuse of effective dual contraception. Drugs with a possible effect on alternating hemiplegia were allowed, at stable doses, throughout the study.

Randomization and blinding {#Sec7}
--------------------------

A computer-generated randomization plan (www.randoweb\@aphp.fr) was used for patient assignment to one of the two treatment sequences, namely triheptanoin followed by placebo, and placebo followed by triheptanoin. For each patient, an inclusion number was provided to the investigators upon connection to the randomization platform. Each inclusion number corresponded to an individual sequence and the patient remained in it throughout the study. Only the pharmacists were aware of the sequence, and dispensed triheptanoin or placebo accordingly. The pharmacists were also responsible for the unblinding process if required by the safety committee. All patients, caregivers and investigators were blinded to the treatment allocation. Triheptanoin and placebo were supplied by Ultragenyx Pharmaceuticals Inc.; they had an identical aspect and were administered in identical amounts.

Statistical analysis {#Sec8}
--------------------

Owing to a lack of previous clinical trials, no efficacy data were available. For the sample size calculation, we postulated a reduction in the total number of paroxysmal events of at least 40% with triheptanoin versus placebo. A sample of 10 patients was required to detect this difference with 80% power at a significance level of 5%.

Efficacy was analyzed on an intention-to-treat (ITT) basis. The ITT population included all randomized patients. The treatment effect was evaluated by comparing the treatment and placebo periods using the paired nonparametric Wilcoxon test, taking into account the small sample size and assuming a non Gaussian distribution. Paired nonparametric Wilcoxon tests were used to verify the absence of a carryover effect. The duration of paroxysmal events was not reported in 6% of cases, and these events were omitted from the calculation of the composite score.

Role of the funding source {#Sec9}
--------------------------

This study was supported by the French Association of Alternating Hemiplegia of Childhood (AFHA) and by the fund from AFER for medical research. Ultragenyx provided the triheptanoin and placebo oils. Ultragenyx was not involved in the study design, conduct, monitoring, data analysis or manuscript preparation.

Results {#Sec10}
=======

Participants {#Sec11}
------------

Ten patients were enrolled in the study (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). All the patients had a proven mutation in the *ATP1A3* gene. Eight patients received a fixed dose of flunarizine (mean 9.4 mg, standard deviation \[SD\] 4.9 mg). Mean daily calorie intake was 2166 kcal (SD 354 kcal). Lipids comprising triheptanoin/placebo oil and a small portion of lipids intake from other sources (daily diet) represented 38% of daily calorie intake. On average, triheptanoin/placebo oil represented 26% of daily calorie intake (target 30%). All the patients were considered compliant with the study treatments, consuming 87% of the recommended triheptanoin/placebo dose (treatment compliance (%) = consumed dose × 100 / prescribed dose).Table 1Baseline characteristics of the trial participantsVariableTotal (*n* = 10)Age at inclusion, y, median (IQR)18.7 (17.9--20.2)Male sex, n (%)4 (40)Age at diagnosis, m, median (IQR)6.9 (0.1--11.4)Mutation of *ATP1A3*  *p.D801N*5 (50) Other mutations5 (50)Total paroxysmal events per week Median (IQR)3.88 (3.19--4.85) Mean (SD)4.39 (1.95)Chronic medications, n (%)9 (90) Number, median (IQR)3 (3--4) Flunarizine, n (%)8 (80) Acetazolamide, n (%)2 (20)Permanent neurologic deficiency Pyramidal syndrome8 (80) Cerebellar syndrome8 (80) Dystonia8 (80) Cognitive/ behavioral dysfunction6 (60)n (%) represents the number of patients (and the percentage of all patients) assessed in each group. *Abbreviations*: *Y* years, *m* months, *IQR* interquartile range \[p25--p75\]

Treatment effects {#Sec12}
-----------------

Changes in the primary and secondary outcome variables are shown in Table [2](#Tab2){ref-type="table"}.Table 2Changes in primary and secondary outcome variablesVariableTriheptanoinPlacebo*p* valueTotal paroxysmal events3.5 (2.1)3.2 (2.1)0.646Motor-epilepticparoxysmal events3.4 (1.9)3.2 (2.0)0.585Composite score1015 (1058)723.9 (767.3)0.059CGI -- patient3.7 (1.5)3.2 (1.0)0.481CGI -- physician3.8 (0.6)3.3 (0.9)0.262Values are means (standard deviation). Total and motor-epileptic paroxysmal events are expressed per week. Wilcoxon test for the difference in changes on each treatment. *Abbreviations*: *CGI* Clinical Global Impression-Improvement scale

Triheptanoin did not reduce the total number of paroxysmal events. Triheptanoin also failed to reduce the number of motor-epileptic paroxysmal events, and the composite score. The CGI-I patient and physician scores were both unchanged between the triheptanoin and placebo periods. There was no difference in interictal neurological manifestations. No carryover effect was detected.

Biochemical analyses {#Sec13}
--------------------

Plasma C3-carnitine measured at the end of each period were significantly higher with triheptanoin than with placebo (1.56 μmol/L versus 0.32 μmol/L; *p* \< 0.01). C5-keto acids levels measured at the end of each period were significantly higher with triheptanoin than with placebo (3-hydroxypentanoate 34.6 μmol/L, 3-ketopentanoate 12.2 μmol/L, versus 0.2 and 0.2 μmol/L, respectively; *p* \< 0.01). These results reflected the proper metabolism of triheptanoin.

Safety {#Sec14}
------

Nineteen adverse events (AE) were reported, of which 5 occurred during the washout period. Fifty percent of patients reported an AE on triheptanoin and 70% on placebo. The AEs corresponding to each treatment period are listed in Table [3](#Tab3){ref-type="table"}. All AEs were transient. Two serious AEs were reported (generalized seizures requiring hospitalization), one during triheptanoin administration and one during the washout period. No study withdrawals occurred. Weight and the body mass index remained stable during the study. Routine laboratory tests showed no noteworthy changes during the study (data not shown).Table 3Adverse eventsAdverse eventTriheptanoin\
(*n* = 6)Placebo\
(*n* = 8)WO\
(*n* = 5)Infection3 (50)5 (63)3 (60)Digestive disorders1 (17)2 (25)0 (0)Others2 (33)1 (13)2 (40)Data are n (%). The denominator is the number of trial participants who had adverse events. *Abbreviation*: *AE* adverse events, *WO* washout period

Discussion {#Sec15}
==========

This randomized, double-blind, placebo-controlled crossover trial failed to show any effect of triheptanoin, at a target dose of 30% of calories, on paroxysmal episodes in patients with alternating hemiplegia of childhood. This argues against a prominent role of a brain energy deficit in these paroxysmal manifestations. Many lessons for future trials in this group of patients were learned during this study.

Many lessons for future trials in this group of patients were learned during this study. These treatments were evaluated in open-label studies or case series. Prophylactic treatment of paroxysmal episodes is a major issue in alternating hemiplegia of childhood. Flunarizine is considered partly effective in some patients but rarely abrogates the attacks. Some degree of improvement is reported in 60--80% of patients in large retrospective series \[[@CR2], [@CR4], [@CR16], [@CR18], [@CR22], [@CR25]\]. A broad range of medications (antimigraine drugs and antiepileptics, particularly benzodiazepines) have been tried, mostly prophylactically, with limited efficacy and/or poor tolerability \[[@CR2], [@CR4], [@CR13]\]. These treatments were evaluated in open-label studies or case series. However, the only available controlled study testing flunarizine in nine AHC patients was not conclusive, likely due to methodological issues \[[@CR26]\]. Our study demonstrates the feasibility of a controlled trial in AHC. Treatment with triheptanoin was not effective to prevent paroxysmal episodes in AHC. Adverse effect were similar in the treatment and placebo groups further indicating that triheptanoin is well tolerated, even in patients with severe neurological disorders.

Our study was based on the hypothesis that paroxysmal episodes are linked to a defective brain energy supply. The following observations are consistent with this hypothesis: i) paroxysmal episodes in AHC share some common triggering factors seen in patent disorders of brain energy metabolism such as glut1 deficiency syndrome \[[@CR2], [@CR12], [@CR23], [@CR24], [@CR27]\]; ii) attacks can generally be terminated by inducing sleep that might reflect a reduced brain energy demand \[[@CR2], [@CR12]\]; iii) an anecdotal report mentions the sustained disappearance of paroxysmal episodes on a ketogenic diet, which efficiently compensates for defective brain glucose metabolism \[[@CR14], [@CR15], [@CR18]\]; iv) neuroimaging studies of interictal brain glucose metabolism showed focal areas of reduced glucose metabolism in AHC patients \[[@CR16]\] and in an AHC mouse model \[[@CR17]\]; and v) Na^+^/K^+^ ATPase dysfunction might influence sodium-dependent brain glucose transportation, particularly in situations where brain energy demand is increased \[[@CR28]--[@CR30]\]. Triheptanoin has been shown to improve cerebral bioenergetics in various conditions associated with brain energy defects \[[@CR19], [@CR20], [@CR31], [@CR32]\]. Its failure to improve paroxysmal episodes in our study does not support a role for cerebral energetic dysfunction in the pathogenesis of AHC. The prevailing hypothesis rather remains that the pump cannot normally utilize ATP or maintain a normal Na+ /K+ gradient.

Although randomized controlled trials are challenging in AHC, they are needed to avoid unnecessary exposure of patients to multiple empirical drug trials. Knowledge and experience gained during the planning, execution and analysis of this study may prove valuable for future controlled studies in this setting: relevant issues include funding, patient recruitment, trial design and duration, and outcome measures. The main financial support provided by the French patients' association for alternating hemiplegia of childhood (AFHA) was critical, as industrial and institutional funding is rarely forthcoming in very rare diseases. AFHA also enabled us to recruit patients from a large geographic area. To optimize recruitment while avoiding exposure of young children to the constraints of a therapeutic trial, we set the minimal age at 15 years. The phenomenology of paroxysmal episodes is different in paediatric and adult patients \[[@CR2]\]. Therefore, our results may not be fully relevant for the paedriatic AHC population. The crossover design also reduced the required number of patients. Given the rarity of AHC, a parallel study design would have increased the risk of baseline differences between the treated and control groups, despite randomization. To limit possible bias due to spontaneous fluctuations in disease severity, we chose relatively long treatment periods (12 weeks) to quantify paroxysmal episodes. To avoid drop-outs, we paid special attention to transport and accommodation during study visits. As AHC patients are extremely vulnerable to stress and change, we allocated extra time for examinations, investigations and discussions, and we proposed hypnotherapy when potentially beneficial. The primary outcome measure was the number of paroxysmal events, as assessed by the patient (or caregiver) and recorded in a handwritten diary. A collection bias is likely thus have occurred although this bias may have been limited by the use of a crossover design (patient is his/her own control). Even for trained experts, it is sometimes challenging to properly characterize the paroxysmal events in AHC. In particular, standardized classification of paroxysmal events with intermingled manifestations is problematic and it may be difficult to distinguish between epileptic seizures and non-epileptic motor events. We therefore choose to study the total number of paroxysmal events as a primary outcome. The main drawback of this approach is a risk of overlooking an effect of the intervention on a specific type of paroxysmal event. Moreover, there are no dedicated tools for evaluating paroxysmal events in this setting. Yet, some data were missing in our study for 6% of episodes. The use of an electronic diary with automated reminders might favor more comprehensive data collection. The functional consequences of each paroxysmal event might be more relevant, along with a separate evaluation of associated pain. Our methodology is a start point and needs to be built on given the above limitations.

Conclusion {#Sec16}
==========

Triheptanoin does not prevent paroxysmal events in alternating hemiplegia of childhood. Our findings do not support a prominent role of a brain energy deficit in alternating hemiplegia. However, randomized placebo-controlled trials are feasible in alternating hemiplegia.
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